Business
Vortex Biosciences appoints Chairman of SAB
Vortex Biosciences appoints Chairman of SAB.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 0706B NetScientific PLC 14 June 2016 \n\n \n \n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nVortex Biosciences appoints Dr. Massimo Cristofanilli as Chairman of newly formed Scientific Advisory Board\n \nLondon, UK - 14 June 2016 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic biomedical and healthcare technology group, notes its portfolio company Vortex Biosciences has appointed Dr. Massimo Cristofanilli as Chairman of its newly formed Scientific Advisory Board.\n \nCommenting on the appointment, NetScientific's Chief Executive Officer, Francois R. Martelet, said: \"Vortex Biosciences is at a pivotal point as its circulating tumour cell enrichment system, the VTX-1, moves towards commercialisation. The appointment of Dr. Cristofanilli, who will be joining to spearhead the creation of Vortex's world class Scientific Advisory Board, will help underpin their clinical strategy as the company moves through this transformational period.\"\n \nVortex Bioscience's press release follows:\n \n \n \nVortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board\n \nLeading Expert on Liquid Biopsies to Provide Perspective on Research and Development of Next Generation Circulating Tumor Cell Enrichment System\n \nMENLO PARK, CA, June 14th - Vortex Biosciences, provider of circulating tumor cell (CTC) enrichment systems, today announced the appointment of Dr. Massimo Cristofanilli as the Chairman of its newly formed Scientific Advisory Board (SAB). The SAB's mission will be to provide valuable scientific and clinical insights, along with strategic guidance in decision-making to support the development and commercialization of Vortex's CTC enrichment system for both the research and diagnostic markets.\n\"Dr. Cristofanilli brings deep expertise in the clinical application of liquid biopsies,\" said Gene Walther, Chief Executive Officer of Vortex Biosciences. \"We are excited he is willing to chair our scientific advisory board and help us execute our clinical strategy as we commercialize our next generation CTC enrichment system, the VTX-1.\"\nMassimo Cristofanilli, MD, an expert in the translational research and treatment of patients with inflammatory breast cancer (IBC), is Pro...